MPAM
IRWD icon

Monarch Partners Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Monarch Partners Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$3.43M Sell
276,579
-26,971
-9% -$306K 1.01% 31
2022
Q3 		$3.15M Buy
303,550
+31,125
+11% +$353K 0.94% 36
2022
Q2 		$3.14M Buy
+272,425
New +$3.21M 0.88% 36

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Monarch Partners Asset Management's IRWD Position: Q4 2022 in Review

Monarch Partners Asset Management reduced its Ironwood Pharmaceuticals (IRWD) stake by 8.9% in Q4 2022, selling an estimated $306K and leaving 276,579 shares worth $3.43M. The position accounts for 1.01% of the portfolio, ranked #31.

Monarch Partners Asset Management first reported a position in IRWD in Q2 2022 and has held it in 3 quarters since. 250 funds tracked by Wall St. Rank hold IRWD as of Q4 2022.

  • Monarch Partners Asset Management held 276,579 shares of Ironwood Pharmaceuticals worth $3.43M as of Q4 2022.
  • Monarch Partners Asset Management sold 26,971 Ironwood Pharmaceuticals shares in Q4 2022, an estimated $306K.
  • Ironwood Pharmaceuticals made up 1.01% of Monarch Partners Asset Management's portfolio in Q4 2022, its #31 holding.
  • Monarch Partners Asset Management first reported a position in Ironwood Pharmaceuticals in Q2 2022 and has held it in 3 quarters since.
  • 250 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.